Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary

The administration announced a new executive order that can impose up to a 100% tariff on some patented drugs, with 0% for companies that sign most-favored-nation pricing deals and onshore production, 20% for firms building U.S. projects (rising to 100% in four years). Firms have negotiation windows of 120 days for larger companies and 180 days for others; the order also sets country caps (EU/Japan/Korea/Switzerland 15%, U.K. 10% currently) and notes previous deals with 17 drugmakers. Separately, metal tariffs remain at 50% for products made entirely of steel/aluminum/copper, while finished goods with >15% metal content face a 25% tariff on the whole value and items with <15% metal face country-specific rates. PhRMA warned higher costs and risk to U.S. investment; the measures represent a sector-moving escalation that increases pricing and supply-chain uncertainty for pharma and metal-intensive industries.

Analysis

The policy moves amplify a structural bifurcation in the pharma supply chain: asset-light innovators and onshore contract manufacturers stand to capture incremental margin as firms rush to secure domestic API and finished‑dose capacity, while import‑dependent generics and specialty suppliers face margin compression and demand destruction. Expect a multi‑year capex cycle in CDMOs and domestic API producers; typical biopharma facility buildouts and regulatory validation mean capacity won’t meaningfully shift for 12–36 months, which creates a window for higher pricing power and backlog-driven revenue upgrades.

Second‑order winners include industrial suppliers of pharmaceutical‑grade chemicals and engineering firms that build sterile fill lines — think sustained demand for stainless steel, clean‑room HVAC, and single‑use systems which could lift orders for select industrial names even if headline pharma equities are volatile. Conversely, distributors and low‑margin generic manufacturers that rely on global sourcing are exposed to both direct cost shocks and downstream volume declines as payers accelerate formulary shifts.

Key risks: legal and trade‑negotiation outcomes could rapidly unwind perceived winners; political bargaining may convert tariffs into targeted carve‑outs or temporary subsidies, trimming upside for builders of US capacity. Monitor near‑term corporate deal announcements and capex guidance (quarterly cadence) as the fastest observable catalysts; absent clear onshoring commitments, expect a continued re‑rating of names most exposed to imported inputs over the next 3–9 months.

Key Decisions for Investors

• Long Catalent (CTLT) — buy shares or 12‑18 month call spread; horizon 6–18 months. Rationale: direct beneficiary of accelerated outsourcing/onshoring; target upside 25–40% if backlog and capacity announcements accelerate. Downside: ~15–20% if tariffs are softened or CDMO competition intensifies; size 2–4% portfolio.
• Long Thermo Fisher (TMO) — buy stock or 18‑month calls for selective exposure to increased demand for sterile manufacturing consumables and API processing; horizon 12–24 months. Risk/reward: conservative 15–30% upside vs 10% downside on cyclical weakness or macro slowdown.
• Short TEVA / Viatris (select one) — outright short or buy puts with 3–9 month horizon. Rationale: import‑dependent generics face highest margin and volume risk. Position sizing small (1–2% portfolio) due to political/legal binary risks; upside amplified if specific product tariffs are applied, but limited by potential carve‑outs.
• Pair trade: long CTLT (or TMO) vs short TEVA — equal notional exposure to isolate policy‑driven spread. Horizon 3–12 months. This hedges market beta while playing the structural winner/loser from reshoring; expected spread expansion of 20–30% under base case.
• Hedging: buy short‑dated protective puts on a broad pharma ETF or large‑cap names (e.g., MRK/PFE) ahead of major corporate pricing/onshoring announcements. Cost small insurance against headline risk and litigation-driven volatility over the next 8–12 weeks.